{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:45:54Z","timestamp":1747205154882,"version":"3.40.5"},"posted":{"date-parts":[[2024,3,25]]},"group-title":"In Review","reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,2,26]]},"abstract":"<title>Abstract<\/title>\n        <p>The antimicrobial resistance crisis (AMR) is associated with millions of deaths and undermines the franchise of medicine. Of particular concern is the threat of bioweapons, exemplified by anthrax. Introduction of novel antibiotics helps mitigate AMR, but does not address the threat of bioweapons with engineered resistance. We reasoned that teixobactin, an antibiotic with no detectable resistance, is uniquely suited to address the challenge of weaponized anthrax. Teixobactinbinds to immutable targets, precursors of cell wall polymers. Here we show that teixobactinis highly efficacious in a rabbit model of inhalation anthrax. Inhaling spores of<italic> Bacillus anthracis<\/italic> causes overwhelming morbidity and mortality. Treating rabbits with teixobactinafter the onset of disease rapidly eliminates the pathogen from blood and tissues, normalizes body temperature, and prevents tissue damage. Teixobactinassembles into an irreversible supramolecular structure of the surface of <italic>B. anthracis<\/italic> membrane, likely contributing to its unusually high potency against anthrax. Antibiotics evading resistance provide a rational solution to both AMR and engineered bioweapons.<\/p>","DOI":"10.21203\/rs.3.rs-3991430\/v1","type":"posted-content","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T05:03:05Z","timestamp":1711342985000},"source":"Crossref","is-referenced-by-count":1,"title":["A Resistance-Evading Antibiotic for Treating Anthrax"],"prefix":"10.21203","author":[{"given":"Dallas","family":"Hughes","sequence":"first","affiliation":[{"name":"NovoBiotic Pharmaceuticals"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Lawrence","sequence":"additional","affiliation":[{"name":"University of Texas Medical Branch"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Peel","sequence":"additional","affiliation":[{"name":"University of Texas Medical Branch"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5003-1108","authenticated-orcid":false,"given":"de Winter","family":"Rosan","sequence":"additional","affiliation":[{"name":"Utrecht University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Losee","family":"Ling","sequence":"additional","affiliation":[{"name":"NovoBiotic Pharmaceuticals"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitti","family":"Niiti","sequence":"additional","affiliation":[{"name":"NovoBiotic Pharmaceuticals"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peoples","family":"Aaron","sequence":"additional","affiliation":[{"name":"NovoBiotic Pharmaceuticals"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhythm","family":"Shukla","sequence":"additional","affiliation":[{"name":"AMOLF"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold","family":"MacGillavry","sequence":"additional","affiliation":[{"name":"Utrecht University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Heine","sequence":"additional","affiliation":[{"name":"University of Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hensel","family":"Martha","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Whorton","family":"Elbert","sequence":"additional","affiliation":[{"name":"University of Texas Medical Branch"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0831-8673","authenticated-orcid":false,"given":"Markus","family":"Weingarth","sequence":"additional","affiliation":[{"name":"Utrecht University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1335-9982","authenticated-orcid":false,"given":"Kim","family":"Lewis","sequence":"additional","affiliation":[{"name":"Antimicrobial Discovery Center, Department of Biology, Northeastern University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/s1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli E","year":"2018","unstructured":"Tacconelli, E. et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18, 318\u2013327, doi:10.1016\/s1473-3099(17)30753-3 (2018).","journal-title":"Lancet Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance C","year":"2022","unstructured":"Antimicrobial Resistance, C. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629\u2013655, doi:10.1016\/S0140-6736(21)02724-0 (2022).","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cell.2020.02.056","article-title":"The Science of Antibiotic Discovery","volume":"181","author":"Lewis K","year":"2020","unstructured":"Lewis, K. The Science of Antibiotic Discovery. Cell 181, 29\u201345, doi:10.1016\/j.cell.2020.02.056 (2020).","journal-title":"Cell"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nature14098","article-title":"A new antibiotic kills pathogens without detectable resistance","volume":"517","author":"Ling LL","year":"2015","unstructured":"Ling, L. L. et al. A new antibiotic kills pathogens without detectable resistance. Nature 517, 455\u2013459, doi:10.1038\/nature14098 (2015).","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.07.038","author":"Shukla R","year":"2023","unstructured":"Shukla, R. et al. An antibiotic from an uncultured bacterium binds to an immutable target. Cell 186, 4059\u20134073 e4027, doi:10.1016\/j.cell.2023.07.038 (2023)."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2018.03.001","author":"Pantel L","year":"2018","unstructured":"Pantel, L. et al. Odilorhabdins, Antibacterial Agents that Cause Miscoding by Binding at a New Ribosomal Site. Mol Cell 70, 83\u201394 e87, doi:10.1016\/j.molcel.2018.03.001 (2018)."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-019-1791-1","article-title":"A new antibiotic selectively kills Gram-negative pathogens","volume":"576","author":"Imai Y","year":"2019","unstructured":"Imai, Y. et al. A new antibiotic selectively kills Gram-negative pathogens. Nature 576, 459\u2013464, doi:10.1038\/s41586-019-1791-1 (2019).","journal-title":"Nature"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/s41564-022-01227-4","article-title":"Computational identification of a systemic antibiotic for Gram-negative bacteria","volume":"7","author":"Miller RD","year":"2022","unstructured":"Miller, R. D. et al. Computational identification of a systemic antibiotic for Gram-negative bacteria. Nature microbiology 7, 1661\u20131672, doi:10.1038\/s41564-022-01227-4 (2022).","journal-title":"Nature microbiology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-023-06799-7","article-title":"A new antibiotic traps lipopolysaccharide in its intermembrane transporter","volume":"625","author":"Pahil KS","year":"2024","unstructured":"Pahil, K. S. et al. A new antibiotic traps lipopolysaccharide in its intermembrane transporter. Nature 625, 572\u2013577, doi:10.1038\/s41586-023-06799-7 (2024).","journal-title":"Nature"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41586-023-06873-0","article-title":"A novel antibiotic class targeting the lipopolysaccharide transporter","volume":"625","author":"Zampaloni C","year":"2024","unstructured":"Zampaloni, C. et al. A novel antibiotic class targeting the lipopolysaccharide transporter. Nature 625, 566\u2013571, doi:10.1038\/s41586-023-06873-0 (2024).","journal-title":"Nature"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41586-021-03899-0","article-title":"Rational design of a new antibiotic class for drug-resistant infections","volume":"597","author":"Durand-Reville TF","year":"2021","unstructured":"Durand-Reville, T. F. et al. Rational design of a new antibiotic class for drug-resistant infections. Nature 597, 698\u2013702, doi:10.1038\/s41586-021-03899-0 (2021).","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nature22308","article-title":"Predictive compound accumulation rules yield a broad-spectrum antibiotic","volume":"545","author":"Richter MF","year":"2017","unstructured":"Richter, M. F. et al. Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature 545, 299\u2013304, doi:10.1038\/nature22308 (2017).","journal-title":"Nature"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41586-023-06760-8","article-title":"Porin-independent accumulation in Pseudomonas enables antibiotic discovery","volume":"624","author":"Geddes EJ","year":"2023","unstructured":"Geddes, E. J. et al. Porin-independent accumulation in Pseudomonas enables antibiotic discovery. Nature 624, 145\u2013153, doi:10.1038\/s41586-023-06760-8 (2023).","journal-title":"Nature"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41586-022-05019-y","article-title":"Teixobactin kills bacteria by a two-pronged attack on the cell envelope","volume":"608","author":"Shukla R","year":"2022","unstructured":"Shukla, R. et al. Teixobactin kills bacteria by a two-pronged attack on the cell envelope. Nature 608, 390\u2013396, doi:10.1038\/s41586-022-05019-y (2022).","journal-title":"Nature"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.281.18.1735","article-title":"Anthrax as a biological weapon: medical and public health management","volume":"281","author":"Inglesby TV","year":"1999","unstructured":"Inglesby, T. V. et al. Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 281, 1735\u20131745, doi:10.1001\/jama.281.18.1735 (1999).","journal-title":"Working Group on Civilian Biodefense. JAMA"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1126\/science.7973702","article-title":"The Sverdlovsk anthrax outbreak of 1979","volume":"266","author":"Meselson M","year":"1994","unstructured":"Meselson, M. et al. The Sverdlovsk anthrax outbreak of 1979. Science 266, 1202\u20131208, doi:10.1126\/science.7973702 (1994).","journal-title":"Science"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1186\/s12879-016-1951-y","article-title":"Alternative pre-approved and novel therapies for the treatment of anthrax","volume":"16","author":"Head BM","year":"2016","unstructured":"Head, B. M., Rubinstein, E. & Meyers, A. F. Alternative pre-approved and novel therapies for the treatment of anthrax. BMC Infect Dis 16, 621, doi:10.1186\/s12879-016-1951-y (2016).","journal-title":"BMC Infect Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02434-16","article-title":"In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis","volume":"61","author":"Steenbergen J","year":"2017","unstructured":"Steenbergen, J., Tanaka, S. K., Miller, L. L., Halasohoris, S. A. & Hershfield, J. R. In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis. Antimicrob Agents Chemother 61, doi:10.1128\/AAC.02434-16 (2017).","journal-title":"Antimicrob Agents Chemother"},{"year":"2004","author":"Davis JA","unstructured":"Davis, J. A. & Schneider, B. R. The gathering biological warfare storm. (Praeger, 2004).","key":"ref19"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9090773","article-title":"Teixobactin Provides Protection against Inhalation Anthrax in the Rabbit Model","volume":"9","author":"Lawrence WS","year":"2020","unstructured":"Lawrence, W. S. et al. Teixobactin Provides Protection against Inhalation Anthrax in the Rabbit Model. Pathogens 9, doi:10.3390\/pathogens9090773 (2020).","journal-title":"Pathogens"},{"key":"ref21","first-page":"257","article-title":"The physiologic responses of Dutch belted rabbits infected with inhalational anthrax","volume":"59","author":"Lawrence WS","year":"2009","unstructured":"Lawrence, W. S. et al. The physiologic responses of Dutch belted rabbits infected with inhalational anthrax. Comp Med 59, 257\u2013265 (2009).","journal-title":"Comp Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9050370","article-title":"Current Status and Trends in Prophylaxis and Management of Anthrax Disease","volume":"9","author":"Savransky V","year":"2020","unstructured":"Savransky, V., Ionin, B. & Reece, J. Current Status and Trends in Prophylaxis and Management of Anthrax Disease. Pathogens 9, doi:10.3390\/pathogens9050370 (2020).","journal-title":"Pathogens"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/978-1-62703-050-2_16","article-title":"Non-compartmental analysis","volume":"929","author":"Gabrielsson J","year":"2012","unstructured":"Gabrielsson, J. & Weiner, D. Non-compartmental analysis. Methods Mol Biol 929, 377\u2013389, doi:10.1007\/978-1-62703-050-2_16 (2012).","journal-title":"Methods Mol Biol"},{"key":"ref24","first-page":"252","article-title":"Transient lipopolysaccharide-induced resistance to aerosolized Bacillus anthracis in New Zealand white rabbits","volume":"63","author":"Yee SB","year":"2013","unstructured":"Yee, S. B., Dyer, D. N., Twenhafel, N. A. & Pitt, M. L. Transient lipopolysaccharide-induced resistance to aerosolized Bacillus anthracis in New Zealand white rabbits. Comp Med 63, 252\u2013261 (2013).","journal-title":"Comp Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.1128\/IAI.00792-06","article-title":"Protective antigen as a correlative marker for anthrax in animal models","volume":"74","author":"Kobiler D","year":"2006","unstructured":"Kobiler, D. et al. Protective antigen as a correlative marker for anthrax in animal models. Infect Immun 74, 5871\u20135876, doi:10.1128\/IAI.00792-06 (2006).","journal-title":"Infect Immun"},{"key":"ref26","first-page":"461","article-title":"Aerosolized Bacillus anthracis infection in New Zealand white rabbits: natural history and intravenous levofloxacin treatment","volume":"60","author":"Yee SB","year":"2010","unstructured":"Yee, S. B., Hatkin, J. M., Dyer, D. N., Orr, S. A. & Pitt, M. L. Aerosolized Bacillus anthracis infection in New Zealand white rabbits: natural history and intravenous levofloxacin treatment. Comp Med 60, 461\u2013468 (2010).","journal-title":"Comp Med"},{"unstructured":"FDA, U. (ed U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research) (Rockville, MD, 2005).","key":"ref27"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1093\/infdis\/167.5.1239","article-title":"Postexposure prophylaxis against experimental inhalation anthrax","volume":"167","author":"Friedlander AM","year":"1993","unstructured":"Friedlander, A. M. et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 167, 1239\u20131243, doi:10.1093\/infdis\/167.5.1239 (1993).","journal-title":"J Infect Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/nature14303","article-title":"Erratum: A new antibiotic kills pathogens without detectable resistance","volume":"520","author":"Ling LL","year":"2015","unstructured":"Ling, L. L. et al. Erratum: A new antibiotic kills pathogens without detectable resistance. Nature 520, 388, doi:10.1038\/nature14303 (2015).","journal-title":"Nature"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"6510","DOI":"10.1128\/AAC.01050-16","article-title":"Dual Targeting of Cell Wall Precursors by Teixobactin Leads to Cell Lysis","volume":"60","author":"Homma T","year":"2016","unstructured":"Homma, T. et al. Dual Targeting of Cell Wall Precursors by Teixobactin Leads to Cell Lysis. Antimicrob Agents Chemother 60, 6510\u20136517, doi:10.1128\/AAC.01050-16 (2016).","journal-title":"Antimicrob Agents Chemother"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"7747","DOI":"10.1039\/d2sc01388f","article-title":"Visualizing the mode of action and supramolecular assembly of teixobactin analogues in Bacillus subtilis","volume":"13","author":"Morris MA","year":"2022","unstructured":"Morris, M. A. et al. Visualizing the mode of action and supramolecular assembly of teixobactin analogues in Bacillus subtilis. Chem Sci 13, 7747\u20137754, doi:10.1039\/d2sc01388f (2022).","journal-title":"Chem Sci"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd2202","article-title":"Multi-targeting by monotherapeutic antibacterials","volume":"6","author":"Silver LL","year":"2007","unstructured":"Silver, L. L. Multi-targeting by monotherapeutic antibacterials. Nature Reviews Drug Discovery 6, 41\u201355 (2007).","journal-title":"Nature Reviews Drug Discovery"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41586-021-03455-w","article-title":"The antibiotic darobactin mimics a beta-strand to inhibit outer membrane insertase","volume":"593","author":"Kaur H","year":"2021","unstructured":"Kaur, H. et al. The antibiotic darobactin mimics a beta-strand to inhibit outer membrane insertase. Nature 593, 125\u2013129, doi:10.1038\/s41586-021-03455-w (2021).","journal-title":"Nature"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"10408","DOI":"10.1021\/bi00107a007","article-title":"Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA","volume":"30","author":"Bugg TD","year":"1991","unstructured":"Bugg, T. D. et al. Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry 30, 10408\u201310415 (1991).","journal-title":"Biochemistry"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1073\/pnas.94.12.6480","article-title":"D-Ala-D-Ala ligases from glycopeptide antibiotic-producing organisms are highly homologous to the enterococcal vancomycin-resistance ligases VanA and VanB","volume":"94","author":"Marshall CG","year":"1997","unstructured":"Marshall, C. G., Broadhead, G., Leskiw, B. K. & Wright, G. D. D-Ala-D-Ala ligases from glycopeptide antibiotic-producing organisms are highly homologous to the enterococcal vancomycin-resistance ligases VanA and VanB. Proc Natl Acad Sci U S A 94, 6480\u20136483 (1997).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1172\/JCI68834","article-title":"Mechanisms of vancomycin resistance in Staphylococcus aureus","volume":"124","author":"Gardete S","year":"2014","unstructured":"Gardete, S. & Tomasz, A. Mechanisms of vancomycin resistance in Staphylococcus aureus. J Clin Invest 124, 2836\u20132840, doi:10.1172\/JCI68834 (2014).","journal-title":"J Clin Invest"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3991430\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3991430\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T05:03:17Z","timestamp":1711342997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3991430\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":36,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-3991430\/v1","relation":{},"subject":[],"published":{"date-parts":[[2024,3,25]]},"subtype":"preprint"}}